Company intelligence / Profile preview

GES Genéricos Españoles Laboratorio

Ownership: Private
Development stage: Commercial

Overview

GES has been providing the Spanish hospital market with a comprehensive line of injectable drugs since 1985. The company is a leading player in the pain and anti-infective segments of the Spanish market[5][6].

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Injectable medications
Industry: Biotech

Drug pipeline

20 assets

epoetin alfa

Commercial

19 more assets in the full pipeline.

Request access →

Partnerships

International distribution partners in European countries, Latin America, and Asia

Beyond the preview

Go deeper on GES Genéricos Españoles Laboratorio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GES Genéricos Españoles Laboratorio.

Explore the full profile